Hemoglobin-based blood substitutes are being developed as oxygen-carrying agents for the prevention of ischemic tissue damage and hypovolemic (low blood volume) shock.

The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for ...

In this article, switching model predictive control (MPC) is proposed for a perturbed max-plus linear system with a reference signal. The lack of stability guarantee for MPC brings difficulties in ...

Increasing the molecular size of acellular hemoglobin (Hb) has been proposed as an approach to reduce its undesirable vasoactive properties. The finding that bovine Hb surface decorated with about 10 ...

5 Tips for Switching From One Psoriasis Biologic to Another Learn how to smoothly transition to a new biologic treatment for psoriasis with these 5 simple steps.

Japan: Researchers have found in a new study that Roxadustat therapy in non-dialyzed chronic kidney disease (CKD) patients may lead to hemoglobin (Hb) overshoot, particularly when switching ...

Protein engineering strategies seek to develop a hemoglobin-based oxygen carrier with optimized functional properties, including (i) an appropriate O2 affinity, (ii) high cooperativity, (iii) limited ...

All three doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40.

The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early type 2 diabetes.

HealthDay News — The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early type 2 diabetes, according ...

WEDNESDAY, June 25, 2025 (HealthDay News) -- The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early type ...